| |
ASAS40
|
BASDAI 50
|
|---|
| |
Response rate, n/N(%)
|
Unadjusted odds ratio
|
Pvalue
|
Response rate, n/N(%)
|
Unadjusted odds ratio
|
Pvalue
|
|---|
| | |
(95% CI)
| | |
(95% CI)
| |
|---|
|
History of prior anti-TNF therapy
| | | | | | |
|
Prior ETN or IFX or both
|
115/305 (37.7)
|
0.41 (0.32 to 0.54)
|
< 0.001
|
128/314 (40.8)
|
0.40 (0.31 to 0.53)
|
< 0.001
|
|
No prior ETN/IFXa
|
518/873 (59.3)
| | |
561/890 (63.0)
| | |
|
Prior TNF antagonist(s)
| | | | | | |
|
ETN only
|
25/81 (30.9)
|
0.93 (0.47 to 1.83)
|
0.083
|
27/81 (33.3)
|
0.98 (0.51 to 1.90)
|
0.033
|
|
IFX only
|
66/150 (44.0)
|
1.64 (0.91 to 2.93)
| |
75/156 (48.1)
|
1.82 (1.03 to 3.20)
| |
|
ETN and IFXa
|
24/74 (32.4)
| | |
26/77 (33.8)
| | |
|
Reason for discontinuation of prior TNF antagonist
| | | | | | |
|
Loss of response
|
46/108 (42.6)
|
2.09 (1.05 to 4.14)
|
0.108
|
47/112 (42.0)
|
2.03 (1.03 to 4.03)
|
0.059
|
|
Intolerance
|
20/52 (38.5)
|
1.76 (0.79 to 3.91)
| |
25/54 (46.3)
|
2.42 (1.11 to 5.30)
| |
|
Lack of responsea
|
16/61 (26.2)
| | |
16/61 (26.2)
| | |
- aUsed as reference value. AS, ankylosing spondylitis; ASAS40, Assessment of SpondyloArthritis international Society 40% response; BASDAI 50, Bath AS Disease Activity Index 50% response; CI, confidence interval; ETA, etanercept; IFX, infliximab; TNF, tumor necrosis factor.
